Patients with acute myocardial infarction who developed defined ventricular tachyarrhythmias were randomly allocated to two groups. The patients (n = 34) in one of the groups received the quaternary ammonium compound N,N-bis (phenylcarbamoylmethyl) dimethylammoniumchloride (QX-572) intravenously as an infusion of 8 mg/kg body weight over 30 minutes. The patients in the other group (n = 33) received saline and acted as controls. The analysis of arrhythmias was based on a continuous electrocardiogram recorded in parallel to routine monitoring during the 24 hours after the start of infusion. Only the detection of ventricular tachycardia or the development of ventricular fibrillation on routine monitoring could induce a change in antiarrhythmic treatment. The incidence of patients with ventricular tachycardia recorded was significantly lower in the QX-572 group (38%) than in the control group (73%). About half the number of patients with ventricular tachycardia recorded on the continuous electrocardiogram were also detected by means of routine monitoring. The number ofpatients with various types ofventricular premature contractions (I-5/min, > 5/min, paired, multifocal, R on T), ventricular tachycardia, and rapid idioventricular rhythm were compared within successive one-hour periods. For all types of ventricular tachyarrhythmias except rapid idioventricular rhythm there was a lower incidence of arrhythmias in the OX-572 group. A reduction was found also in the total number of observed I-minute intervals containing the various ventricular tachyarrhythmias. The difference between the groups remainedfor at least i6 hours, indicating a long duration of action after a single infusion of QX-572. Thefirst hour was also analysed in successive 5-minute periods and it was demonstrated that the effect of QX-572 started after 5 minutes and was fully developed after i5 minutes. Of 26 patients with ventricular tachycardia detected on monitoring, I3 received QX-572 (8mglkg body weight) and 13 lignocaine (75 mg) as an intravenous bolus followed by an infusion of 4 mg/min). The number of patients developing further runs ofventricular tachycardia did not differ between the QX-572 (6) and the lignocaine (8) groups.
disorders were abolished by QX-572 (Katz, I965; Schwartz, Stapleton, and Covino, i967) . When QX-572, 8 mg/kg body weight, was given to i2 patients with serious ventricular tachyarrhythmias including recurrent ventricular fibrillation refractory to other antiarrhythmic drugs, the arrhythmias vanished in almost all patients (Ryden et al., I974b) . In these studies QX-572 seemed to have a rapid onset and a long duration of action. However, other factors such as the previous administration of antiarrhythmic drugs, incomplete detection of arrhythmias, and the lack of suitable controls may have influenced the results.
The present investigation was planned to provide a more thorough appraisal of QX-572. By comparing a treatment and a control group, it was aimed to assess not only its antiarrhythmic effect but also the time of onset and duration of action of the drug, and any side effects which may result from its use.
Subjects and methods
Patients admitted to the coronary care unit (CCU) with proven or suspected acute myocardial infarction were considered for the study if they developed ventricular tachyarrhythmias of one or more of the following types: i) > 5 ventricular premature contractions per minute; 2) paired ventricular premature contractions; 3) multifocal ventricular premature contractions; 4) R on T ventricular premature contractions; and 5) ventricular tachycardia defined as 3 or more ventricular premature contractions in sequence at a rate exceeding IOO a minute. Patients with second-or third-degree atrioventricular block, right and left bundle-branch block, or atrial fibril-lation or flutter were excluded. Arrhythmia detection and electrocardiographic interpretation were performed by means of the routine monitoring in the coronary care unit supplemented by a I2-lead electrocardiogram when necessary for accurate diagnosis. Conventional criteria were used for the definition of arrhythmias and conduction disturbances (Goldman, I970) .
The presence of frank pulmonary oedema or hypotension (systolic blood pressure below go mmHg (12 kPa)) excluded the patient from the study as did antiarrhythmic treatment instituted before admission to the coronary care unit. The patients accepted for the study were randomly allocated to either a QX-572 group or a control group. QX-572 (Astra, S6dertalje, Sweden) in a total dose of 8 mglkg body weight was infused as a 0.5 per cent solution in saline over 30 minutes. The patients in the control group received the corresponding volume of saline. The infusions were givenbymeans of an infusion pump (Infusomat, Braun, Melsungen, West Germany) into an arm vein. Informed consent to drug infusion was obtained from the patients before randomization.
Except for the administration of antiarrhythmic drugs, the patients were managed according to the routine of the coronary care unit (Henning and Holmberg, 197I) .
Monitoring was continued throughout the study and judgement concerning further antiarrhythmic treatment was based on this routine arrhythmia-detecting system. After the start of the initial drug infusion no further antiarrhythmic treatment was permitted for I5 minutes unless ventricular fibrillation occurred. Thereafter, the detection of ventricular tachycardia was accepted as an indication for a change in treatment. The patients originally on QX-572 then received lignocaine (XylocainR, Astra, Sodertdlje, Sweden). An intravenous bolus injection of 75 mg over 2 minutes was immediately followed by an infusion of 4 mg/min by means of an infusion pump (Perfusor, Braun, Melsungen, West Germany). The infusion rate could be reduced if suspicions of side effects occurred. The patients in the saline group were at this stage randomly given either QX-572 or lignocaine. The dosages and modes of administration of the drugs were as described. If ventricular tachycardia was detected once more and I5 minutes had passed after the last administration of drug, patients on QX-572 received lignocaine. Patients already on this drug were treated without any predetermined rules and so were patients developing ventricular fibrillation, irrespective of when it occurred. If persistent hypotension, pulmonary oedema, atrioventricular block of second or third degree, bundle-branch block, atrial flutter, or atrial fibrillation were detected treatment was given as appropriate.
The monitored electrocardiograph was also continuously recorded using an ink-writing recorder (Mingograf 8i, Siemens-Elema AB, Stockholm, Sweden), with a paper speed of I0 mm/s. The recording was always continued for 24 hours from the start of the first drug. The time of drug administration and other interventions were recorded. All data concerning the occurrence of ventricular tachyarrhythmias were derived from the continuous electrocardiogram. This method of arrhythmia detection has previously been described in detail by Mogensen (1970) . The electrocardiogram from each patient was analysed minute by minute. A I-minute interval was accepted only if every QRS complex could be identified. Then the accepted I-minute intervals were classified with regard to the presence or absence of ventricular arrhythmias according to the following criteria. i) Ventricular premature contraction = a QRS complex with a duration >o.io s and a configuration differing from that of the basic QRS complex. It should not be preceded by a premature P wave. If present, the contractions were subgrouped as follows: a) I to 5/min; b) > 5/min; c) all = a + b; d) monofocal = QRS complexes of only one type; e) multifocal = QRS complexes of at least two configurations within a I-minute interval; f) paired = two ventricular premature contractions in sequence; g) R on T = ventricular premature contractions starting within 85 per cent of the QT time of the preceding QRS complex.
2) Ventricular tachycardia = runs of > 3 ventricular premature contractions in sequence with a QRS rate exceeding Ioo/min. To be accepted as ventricular tachycardia there should not be any suspicion of a supraventricular tachycardia with aberrant conduction.
3) Ventricular fibrillation = rapid and irregular oscillations of the baseline. 4) Rapid idioventricular rhythm=runs of >3 ventricular premature contractions: at a rate below ioo/min. 5) Ventricular asystole =a RR-interval> 3 s. After the classification of the i-minute intervals the information obtained was compiled into i-hour long periods, and also into 5-minute long periods during the first hour after drug administration. A comparison was made of the overall incidence of ventricular tachycardia in the different groups of patients, as well as the number of i-hour and 5-minute periods containing ventricular tachyarrhythmias. Finally, the percentage of i-minute intervals containing various types of ventricular tachyarrhythmias were compared between the groups. In addition the content of supraventricular tachyarrhythmias, bundle-branch block, and atrioventricular block were appraised for each i-hour or 5-minute period.
Heart rate and brachial artery pressure (by cuff) were measured before the start of the infusion, every io minutes during the first hour, and afterwards at go and i50 minutes. Thereafter these measurements were performed according to usual routine. Venous blood samples were taken at 30, 6o, i20, and 240 minutes after the start of infusion and QX-572 in plasma was determined as described by Ryden, Berlin, and Treiber (I974a) . Blood samples were also taken on the day of study and one and six days later for serum electrolytes and tets of renal and hepatic function.
To compare the clinical and laboratory findings in the two groups the following tests were used: Student's ttest for independent means, X2-test, and Fisher's exact probability test for the test of independent proportions (large and small sample, respectively), and KolmogorovSmirnov's two-sample test for comparison of distributions. The mean changes in the laboratory assessments were compared between the groups using the following ratio, which for large samples is approximately distributed as the standard normal deviation: di-d2 SE2 + SE2 This test was also used to compare the mean changes in blood pressure and heart rate after the injections of QX-572 or saline. To test for antiarrhythmic effect either the X2-test or Fisher's exact probability test was used depending on the size of the samples. Details of the test methods are given by Siegel (i956) and Snedecor and Cochran (i967) .
Results
Composition of patient material Altogether 98 patients were admitted to the study (Fig. i) patients in the saline group forming the basis for the comparative study. Some characteristics of the patients are presented in Table i . The groups were also compared as regards the presence of hypertension, diabetes, and digitalis treatment, as well as heart rate and arterial blood pressure at start of therapy, and potassium, creatinine, and bilirubin in serum. Except that a history of angina pectoris lasting longer than one month was more common in the QX-572 group (P < o.oi), no significant differences were found between the two groups. The distribution of patients by types of ventricular tachyarrhythmias constituting the reason for entering the study are shown in Table 2 . In some patients more than one type of arrhythmia was present.
In the QX-572 group 97.I per cent of the i-minute intervals were suitable for electrocardiographic analysis. The corresponding figure for the saline group was 96.6 per cent. (38%) in the QX-572 and 24 (73 %) in the saline group had developed this arrhythmia. The lower incidence in the QX-572 group was statistically significant (P < o.oi). The total amount of QX-572 administered to patients developing ventricular tachycardia (mean ± SE = 620 ± 25 mg) did not differ significantly from the amount given to those who did not (593 ± I5 mg). Nor were there any significant differences in plasma levels of QX-572 between patients with and those without ventricular tachycardia. When comparing the incidence of one-hour and one-minute periods containing ventricular tachyarrhythmias, the patients remained in the respective groups until a change in therapy was instituted because of the detection of ventricular tachycardia on the routine monitors. Of the 24 saline patients with ventricular tachycardia, I2
were detected (5o%). The corresponding figure in the QX-572 group was 6 out of I3 (46%). In addition 3 patients in the QX-572 group were falsely classified as having ventricular tachycardia caused by artefacts in 2 cases, and with no obvious reason in I.
In the QX-572 group a total of 67I and in the saline group 567 one-hour periods were observed. For all types of ventricular tachyarrhythmias except rapid idioventricular rhythm there was a lower incidence (P < o.ooi) of one-hour periods with arrhythmias in the QX-572 group (Table 3 ). In Fig. 3 the number of patients with each of the different types of ventricular premature contractions are presented in consecutive one-hour periods.
Except for rapid idioventricular rhythm the total number of one-minute intervals with the various types of ventricular tachyarrhythmias was less (P <o.OOi) in the QX-572 compared with the saline group. As an example the proportion of oneminute intervals with I to 5 and more than 5 ventricular premature contractions per minute for consecutive one-hour periods are presented in Fig. 4 . The occurrence of ventricular arrhythmias remained lower in the QX-572 group throughout the major part of the 24-hour long period of observation ( Fig. 3-4) .
During the first hour of observation the incidence of ventricular tachyarrhythmias in the QX-572 group was reduced. The reduction was obvious after about i5 minutes. A small increase, to less than initial levels, was noted during the last 20 minutes of the hour. In the saline group the incidence of ventricular arrhythmias remained essentially stable during the first hour. The difference between the groups became statistically significant during the third 5-minute period (Fig. 5 ).
QX-572 was given to I3 patients and lignocaine to another I3 because of ventricular tachycardia. Of these patients 8 had originally been allocated to the QX-572 and 6 to the saline group. The remaining i2 were found to have ventricular tachycardia during the observation period after a saline infusion. The incidence of patients developing further episodes of ventricular tachycardia (Fig. 6) The incidence of supraventricular arrhythmias was low in both the QX-572 and the saline group. In addition to some supraventricular premature beats occasional short runs of ectopic atrial tachy- group.bmj.com on June 26, 2017 -Published by http://heart.bmj.com/ Downloaded from arrhythmias were observed without any preponderance for either group.
Effects on blood pressure, heart rate, and laboratory findings QX-572 caused an increase in heart rate only I0 minutes after the start of infusion, which was maximal (mean ± SE = 30 ± 3 beats/min) at the end of the infusion and still significant (P < .OOI) 60 minutes after the completion of the infusion. The systolic and diastolic blood pressure increased from I0 minutes after the end of the infusion of drug (P<O.OI). The increase was maxial I0 minutes later (mean systolic±SE= 23±3 mmHg (3.i + 0.4 kPa); mean diastolic±SE=I2±2 mmHg (I.6±0.3 kPa); P<o.ooi) and still significant (P<o.oi) at the observation 6o minutes after the completion of infusion (Fig. 7) . The comparison of laboratory findings in the groups of patients did not reveal any untoward effects of QX-572.
Side-effects
The side-effects of all 58 patients receiving QX-572 have been considered. Of these patients, 5i
constituted the original QX-572 group (Fig. I ) and 7 were given QX-572 because of ventricular tachycardia. One received QX-572 for only 6 minutes (without any side-effects) before the onset of ventricular fibrillation causing a subsequent change in therapy. This patient has been omitted from further evaluation. The saline group consists, as regards the occurrence of side-effects, of 40 patients. These were the original 47 reduced by the 7 who were later given QX-572. In both groups some patients also received lignocaine. There were only few and unimportant conduction disturbances and periods of asystole without any differences between the groups. Subjective sideeffects of various types were reported by patients receiving QX-572 (Table 4 ). The most common (25%) was circumoral paraesthesia, often combined with numbness of the tongue. This usually started I5 to 20 minutes after the start of QX-572 infusion and lasted until about i5 minutes after completion of drug administration. Chest pain (i2%) was the next most common subjective side-effect and Of the 98 patients admitted to the study, 2 died during the period of observation and 4 later during the stay in hospital. One patient belonged to the QX-572 and 5 to the saline group. Data concerning these patients are presented in Table 6 . In no case could death be related to any of the drugs used in the investigation.
Discussion
Patient selection and design of study Ventricular tachyarrhythmias complicating acute myocardial infarction seem to be the most important indication for QX-572. Patients presenting this problem were, therefore, chosen for the evaluation of the properties of the drug. In this type of patient the clinical condition and the incidence of ventricular tachyarrhythmias changes from one time to another. Thus, conclusions concerning the influence of an antiarrhythmic agent can be drawn only after comparison with an appropriate control group. The saline and QX-572 groups were comparable in all respects except for the history of angina pectoris. This dissimilarity cannot reasonably explain the difference in the occurrence of ventricular tachyarrhythmias.
The study was not performed as a double-blind trial. Knowledge of actual treatment was considered important in case of emergency. Also it was known that the administration of QX-572 would be apparent because of an increase in heart rate soon after the start of the infusion (Ryden et al., I974b) .
The single-blind design could not introduce any bias with reference to the final detection of ventricular tachyarrhythmias. This was based on continuous electrocardiographic recording interpreted according to defined criteria. The detection rate was comparable to that previously found in the coronary care unit (Ryden, Holmberg, and Waldenstrom, I974c) .
Arrhythmia detection by nurses is not satisfactory for scientific purposes (Mogensen, I970; Romhilt et al., 1973; Ryden et al., I974c) . Intermittent sampling of the electrocardiogram has been widely used for the evaluation of antiarrhythmic efficacy but allows erroneous conclusions to be drawn (Ryden, Waldenstrom, and Holmberg, I974d) . In the present study the results were, therefore, based on the interpretation of continuous electrocardiographic recordings.
Patients were admitted to the study according to the criteria suggested by Lown et al. (I967) as indications for treatment of ventricular arrhythmias in acute myocardial infarction. Under carefully controlled conditions it has been shown possible to delay the institution of antiarrhythmic treatment until the development of ventricular tachycardia (Mogensen, 1970) . In the present study the detection of ventricular tachycardia led to a change of therapy. This implies successive withdrawal of patients with a specific type of arrhythmia. Keeping this limitation in mind, it is still possible to draw conclusions from the comparative study. It is important that the rate of withdrawal was relatively low and proportional in the two groups.
Antiarrhythmic efficacy
The QX-572 and saline groups were compared in different ways as regards the presence of ventricular tachyarrhythmias. In all respects QX-572 turned out to be an effective antiarrhythmic agent and the present study clearly confirms previous experience with the drug (Katz, I965; Schwartz et al., I967; Ryden et al., I974b) . QX-572 is not only effective in the overall reduction of ventricular tachyarrhythmias but also diminishes the occurrence ofindividual types of ventricular premature contractions (Fig. 3) . Of interest is the extremely low incidence of R on T ventricular premature contractions in the QX-572 group. This type of arrhythmia has been found to be especially ominous as a precursor of ventricular fibrillation in man (Mogensen, I970; Dhurandhar, MacMillan, and Brown, 197I) . In a recent experimental study on baboons (Bruyneel and Opie, I973) it was found that ventricular tachycardia, ventricular bigeminy, and R on T ventricular premature contractions were the three types of ventricular tachyarrhythmias correlated to later ventricular fibrillation. The only type of ventricular tachyarrhythmia which was not reduced by QX-572 was rapid idioventricular rhythm. This arrhythmia has been described as relatively benign and not by itself necessitating the initiation of antiarrhythmic treatment (Rothfeld et al., I968; Norris, Mercer, and Yeates, I970) . Lignocaine has also been shown to be ineffective against rapid idioventricular rhythm (Mogensen, I970) .
Onset and duration of action The onset of action is rapid, starting after 5 minutes (Fig. 5) . A limited recurrence of ventricular tachyarrhythmias was noted 40 minutes after the start of infusion of QX-572. Contrary to previous statements (Ryden et al., 1974b) , this observation supports the hypothesis that the initial antiarrhythmic effect of QX-572 is in some way linked to the drug-induced increase in heart rate. Treatment of ventricular tachyarrhythmias by means of increase of heart rate was originally described by Swedberg and Malm (I964) and Sowton, Leatham, and Carson (I964) . This explanation for the antiarrhythmic properties is not applicable after the initial period when the effect remains despite the heart rate returning to normal.
The results indicate that the suppression of ventricular tachyarrhythmias, caused by a single infusion of QX-572, remains for a long period of time.
This is in accordance with previous findings (Schwartz et al., I967; Ryden et al., I974b) . It is difficult to establish the exact duration. The diminishing difference between the groups seems to be caused by a reduction of the incidence in the saline group rather than an increase in the QX-572 group. However, a significant difference in the occurrence of ventricular tachyarrhythmias still remains after as long as i6 hours (Fig. 3 and 4) . A proportionately large number of QX-572 patients was found to have ventricular tachycardia during the first 4 hours after the infusion (Fig. 2) (Ryden et al., 1974b) . Other quaternary ammonium compounds active against ventricular tachyarrhythmia have also been found to have a long duration of action (Romhilt et al., I972; Gillis et al., I973; Kniffen et al., I974) .
Dose and plasma levels
The efficacy of QX-572 as judged by the incidence of ventricular tachycardia was not related to the absolute amount infused or the plasma levels. Based in part on the present group of patients, poor correlation was found between the amount of drug infused and plasma levels (Ryden et al., 1974a) . This suggests that a standardized dosage of QX-572 could be given rather than 8 mg/kg body weight; this would have practical advantages.
Possible contraindications
Patients with atrial flutter and fibrillation were not accepted for this study nor were patients with bundle-branch block. The presence of such abnormalities would have introduced a risk of erroneous differentiation between ventricular premature contractions and aberrantly conducted QRS complexes of supraventricular origin. A clinically important question is whether atrial fibrillation and flutter should contraindicate the use of QX-572. Attempts to control chronic atrial fibrillation by means of QX-572 were not successful (Schwartz et al., i967) . Furthermore QX-572 in the doses used increased conduction velocity through the atrioventricular node (Ryden, Olsson, and Kvasnicka, I975b) . Thus, the use of QX-572 may increase the ventricular rate in the presence of these arrhythmias. In the present study no evidence was found of a depressent effect of QX-572 on cardiac conduction. The very few and brief episodes of conduction abnormalities were most likely caused by the disease itself. Until further experience is gained, atrioventricular block of second and third degree should, however, be regarded as contraindications to the drug.
Side-effects
The initial fall in blood pressure during the infusion is explained by peripheral vasodilatation and can to a large extent be avoided by using a slow rate of infusion (Schwartz et al., I967; Ryden et al., I975a) .
The QX-572 induced increase of heart rate is probably caused by increased sympathetic drive (Ryden et al., I975b; U. Eliasson and L. Ryden, unpublished data) . Whether the same mechanism causes the late increase in blood pressure is not known. At the time when the increase in blood pressure is greatest, about 20 minutes after the completion of QX-572 infusion, the heart rate has largely reverted to the preinfusion level. The changes in heart rate and blood pressure will increase the oxygen demand of the heart (Robinson, I967; Holmberg, Serzysko, and Varnauskas, 1971) . Chest pain was reported as a side-effect by I2 per cent of the patients treated with QX-572 (Table 4 ) and may be explained by such mechanisms. Chest pain was not recorded as a side-effect in any of the patients in the saline group, though some patients had received analgesic drugs. When a close evaluation of the consumption of analgesics and anti-emetics was performed there was no difference between the two groups ( Table 5 ). The time period 0 to 3 hours was chosen to cover the period of changes in blood pressure and heart rate after QX-572 infusion. The probable explanation for the lack of records of chest pain and nausea as side-effects in the saline group is the single-blind design. Saline has not been thought to induce such symptoms and they have been interpreted as natural symptoms of the disease.
QX-572 can of course not be excluded as the cause of chest pain and nausea but neither, on the other hand, should the possible association be overemphasized.
Using the release of serum aspartate aminotransferase as a measure of the infarction size (Kibe and Nilsson, i967) , no difference was found between patients receiving QX-572 and saline. No cerebral side-effects were observed in the QX-572 group. Since quaternary ammonium compounds do not cross the blood-brain barrier (Goodman and Gilman, I970), this was not to be expected. Circumoral paraesthesia has in previous studies been experienced by almost all patients receiving QX-572 (Ryden et al., I975a b) . The explanation for the present comparatively low incidence of para-esthesia is probably that the patients were informed about this side-effect and not subsequently questioned about its occurrence. QX-572 is a potent local anaesthetic. The paraesthesia parallels the peak level of QX-572 in plasma and is probably explained by local anaesthesia of highly perfused tissues.
QX-572 and lignocaine
The present study included a comparison of lignocaine and QX-572 on a selected group of patients who all had ventricular tachycardia. The results suggest that the antiarrhythmic efficacy of these drugs is comparable. This is also supported by the fact that of 6 patients with ventricular tachycardia after QX-572, 4 still had runs of ventricular tachycardia after lignocaine. The dose of lignocaine was comparatively high (Harrison and Alderman, I972) and in some patients the infusion rate had to be reduced, usually because of cerebral side-effects. Thus, it may be argued that a single dose of QX-572 has been compared to intensive lignocaine treatment.
Concluding remarks QX-572 in the present study proved to be an effective agent against ventricular tachyarrhythmias complicating acute myocardial infarction. The rapid onset of action and long duration together with the lack of cerebral side-effects are advantageous properties. An initial decrease in blood-pressure during the infusion of QX-572 can be diminished by a short pause followed by a reduced rate of infusion. The increase in heart rate and late rise of blood pressure are clinically the most important sideeffects. Results from animal experiments suggest that the increase in heart rate, can be modified by the use of beta-blocking agents (U. Eliasson and L. Ryden, unpublished data) .
QX-572 is considered to be a valuable supplement to the therapeutic arsenal in the coronary care unit but should at present be used only on strict criteria. The most important of these are probably refractory ventricular arrhythmias. 
